Clinical Trial Update: NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis [Phase 4]

View source ↗

Summary

Phase 4 trial update completed evaluating Nexium (esomeprazole) for moderate to severe erosive esophagitis and related reflux conditions.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Erosive Esophagitis
• Gastroesophageal Reflux Disease
• Reflux Esophagitis

Drugs mentioned

• Nexium (esomeprazole)

Snippet

Sponsor: AstraZeneca | Conditions: Erosive Esophagitis, Reflux Esophagitis | Phase 4 | Status: COMPLETED